Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26858667 | 0.82 | CYP2D6 (0.43) | KDM4EALDH1A1HTTIDO1 | |
| SCHEMBL7800224 | 0.81 | SIGMAR1 (0.53) | MAOBSMN1; SMN2IDO1POLBMEN1 | |
| SCHEMBL21153206 | 0.79 | SLC1A1 (0.43) | MAOBKDM4EIDO1AGXTPOLB | |
| SCHEMBL8061284 | 0.73 | CASR (0.72) | CASR | |
| SCHEMBL30245831 | 0.73 | KDM4E (0.77) | CASRBCHEKDM4EALDH1A1HTT | |
| SCHEMBL8880839 | 0.73 | KDM4E (0.77) | CASRBCHEKDM4EALDH1A1HTT | |
| SCHEMBL10775771 | 0.73 | BCHE (0.52) | BCHEMAOBSMN1; SMN2POLB | |
| SCHEMBL5271341 | 0.73 | BCHE (0.64) | CASRBCHEMAOBSLC2A1MEN1 | |
| SCHEMBL5266446 | 0.72 | BCHE (0.62) | CASRBCHEMAOBKDM4EALDH1A1 | |
| SCHEMBL2954251 | 0.71 | CASR (0.60) | CASRTAAR1KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | CASR 3062/4885TAAR1 2452/4885BCHE 36/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | CASR 2783/4885TAAR1 1901/4885BCHE 121/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | CASR 3062/4885TAAR1 2452/4885BCHE 36/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | CASR 4416/4885TAAR1 1767/4885BCHE 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.